According to Shinpoong Pharm's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -13.9685. At the end of 2022 the company had a P/E ratio of -30.7.
Year | P/E ratio | Change |
---|---|---|
2022 | -30.7 | -78.29% |
2021 | -141 | -111.27% |
2020 | > 1000 | 1733.81% |
2019 | 68.3 | -37.81% |
2018 | 110 | -65.46% |
2017 | 318 | -2414.18% |
2016 | -13.7 | -110.72% |
2015 | 128 | 181.56% |
2014 | 45.5 | 44.27% |
2013 | 31.6 | 29.82% |
2012 | 24.3 | 256.69% |
2011 | 6.82 | 32.63% |
2010 | 5.14 | 16.21% |
2009 | 4.42 | -18.69% |
2008 | 5.44 | -48.88% |
2007 | 10.6 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.